Lunai Bioworks Inc. (LNAI): Nasdaq/NYSE listing notice — Enochian BioSciences receives second Nasdaq delisting notice over delayed 10-Q filing

Lunai Bioworks Inc.

Nasdaq notified Enochian on Nov 23, 2022, of non-compliance with Listing Rule 5250(c)(1) for failure to file Form 10-Q for period ended Sep 30, 2022.
This follows a prior notice on Oct 17, 2022, for delayed Form 10-K (year ended Jun 30, 2022).
Delay attributed to ongoing work by a third-party valuator on a company asset.
Company must submit a compliance plan by Dec 16, 2022; if accepted, Nasdaq may grant until Apr 11, 2023 to file.
Failure to regain compliance could lead to delisting from Nasdaq.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Lunai Bioworks Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

November 23, 2022, Enochian Biosciences Inc. (the “ Company ”) received a notice (the “ Notice ”) from The Nasdaq Stock Market LLC (“ Nasdaq ”)stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended September 30, 2022 (the “ Form 10-Q ”), the Company remains in non-compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the Securities and Exchange Commission. As previously disclosed on Form 8-K filed with the Securities and Exchange Commission on October 21, 2022, on October 1

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Lunai Bioworks Inc. filing history →

Source: SEC EDGAR

accession 0001731122-22-002068

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.